Key result
Intracoronary infusion of CGRP dilated normal segments of the left anterior descending artery by 22.6% (P<0.001) and caused variable dilatation of atheromatous epicardial arteries.
Why the study?
Does intracoronary CGRP dilate normal and atheromatous coronary arteries and resistance vessels in humans?
Population
20 patients
Comparison
Intracoronary infusion of calcitonin… vs Baseline, followed by intracoronary adenosine…
Design
Other
Follow-up
Acute (during infusion)
Authors
Loading...
CGRP coronary effects in atherosclerosis remain exploratory; leaves open vasodilator potential pending larger studies.
Does intracoronary CGRP dilate normal and atheromatous coronary arteries and resistance vessels in humans?
Effect estimate: 22.6% dilation (95% CI +/- 8%)
p-value: p=<0.001
CGRP is a potent dilator of normal epicardial coronary arteries but has little effect on coronary resistance vessels in nonischemic myocardium and causes variable dilatation in atheromatous arteries.
Ludman et al. (1991) studied Atheromatous coronary artery disease (n=20). Calcitonin gene-related peptide (CGRP) vs. Adenosine and glyceryl trinitrate (GTN) was evaluated on Change in left anterior descending artery (LAD) diameter at an angiographically normal site (22.6% dilation, 95% CI +/- 8%, p=<0.001). Intracoronary infusion of CGRP dilated normal segments of the left anterior descending artery by 22.6% (P<0.001) and caused variable dilatation of atheromatous epicardial arteries.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: